Fusion Antibodies PLC
LSE:FAB
Net Margin
Fusion Antibodies PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
7.6m GBP |
-90%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
152.8B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
143.8B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.5B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.9B USD |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
197.7B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.7B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.9B EUR |
7%
|
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Fusion Antibodies PLC's most recent financial statements, the company has Net Margin of -90.3%.
You don't have any saved screeners yet